Stephanie S. Watowich

May 3, 2023 | nature.com | Joon Seok Park |SArah Johnson |Sarah Johnson |Golnaz Morad |Stephanie S. Watowich |Jennifer Wargo | +3 more

AbstractThe gut microbiota is a crucial regulator of anti-tumour immunity during immune checkpoint inhibitor therapy. Several bacteria that promote an anti-tumour response to immune checkpoint inhibitors have been identified in mice1,2,3,4,5,6. Moreover, transplantation of faecal specimens from responders can improve the efficacy of anti-PD-1 therapy in patients with melanoma7,8.